Alnylam Pharmaceuticals (ALNY) reported $1.17 billion in revenue for the quarter ended March 2026, representing a year-over-year increase of 96.4%. EPS of $1.99 for the same period compares to -$0.01 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $1.13 billion, representing a surprise of +2.91%. The company delivered an EPS surprise of +39%, with the consensus EPS estimate being $1.43.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Alnylam performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Product revenues, net: $1.04 billion versus the six-analyst average estimate of $1.01 billion. The reported number represents a year-over-year change of +121.1%. Net Product Revenue - Total Rare: $125.72 million versus $135.02 million estimated by five analysts on average. Net Product Revenue - Total TTR: $910.41 million versus $875.25 million estimated by five analysts on average. Revenues- Net revenues from research collaborators: $82.08 million versus $51.48 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -17.3% change. Revenues- Royalty revenue: $48.97 million versus the four-analyst average estimate of $60.3 million. The reported number represents a year-over-year change of +85%. Net Product Revenue- Oxlumo: $51.32 million versus $52.47 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +21.9% change. Net Product Revenue- Givlaari: $74.39 million compared to the $82.55 million average estimate based on four analysts. The reported number represents a change of +11.1% year over year. Net Product Revenue- Amvuttra: $889.93 million versus the three-analyst average estimate of $827.32 million. The reported number represents a year-over-year change of +187.1%. Net Product Revenue- Onpattro: $20.48 million versus $29.57 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -58.6% change.View all Key Company Metrics for Alnylam here>>>
Shares of Alnylam have returned -8.4% over the past month versus the Zacks S&P 500 composite's +12.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power .
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).